Hensoldt's €10.35 Billion Backlog: Why Record Orders and a Monday Rally Haven't Settled the Debate
Published on 08/03/2026 at 16:50 | Redaktion boerse-global.de
The arithmetic at Hensoldt looks straightforward on paper: order intake doubled, the backlog hit an all-time high, and revenue growth came in well into double digits. Yet the market's reaction to those half-year figures has been anything but uniform — and the gap between the company's operational momentum and its share price performance has become the central talking point among investors.
Monday brought a measure of relief. The Taufkirchen-based sensor and optronics specialist climbed 6.97 percent to €85.32, clawing back a chunk of Friday's losses, when the stock shed roughly five percent in the wake of the results release. Even after that bounce, however, the shares remain 25.87 percent below the 52-week high of €115.10 set in early October — a reminder that the recovery is still very much a work in progress.
The Numbers Behind the Noise
Strip away the market's mood swings and the underlying figures are hard to argue with. First-half revenue advanced 23.6 percent to €1.167 billion, while adjusted EBITDA rose 28.5 percent to €137 million, lifting the adjusted margin to 11.8 percent from 11.3 percent a year earlier. Order intake more than doubled to €2.812 billion, pushing the book-to-bill ratio to 2.4x against 1.5x in the prior-year period. The backlog swelled to a record €10.356 billion, giving the company multi-year visibility that most industrial peers would envy.
The optronics division deserves particular attention. Its order intake nearly sextupled to €971 million, driven by framework agreements for thermal imaging devices and targeting optics for armoured vehicles including the Schakal and Puma programmes. Management has also been busy expanding the technological footprint: the partnership with Helsing produced the first order for the CAIRAS missile warning system earmarked for the CA-1 Europa autonomous combat aircraft, while a collaboration with Ukrainian firm Fire Point under the Project Freyja initiative adds another dimension to the portfolio.
Should investors sell immediately? Or is it worth buying Hensoldt?
Why the Skepticism Persists
For all the headline strength, the bears have identifiable ammunition. The negative free cash flow of minus €136 million in the first half is one obvious pressure point. The margin trajectory is another: despite the improvement, the 11.8 percent adjusted margin remains a long way from the full-year guidance of 18.5 to 19.0 percent, which puts considerable weight on the fourth quarter — traditionally when Hensoldt books most of its project milestones.
mwb Research, the most vocal sceptic on the stock, reaffirmed its "Sell" rating on Monday with a fair value of just €62. The house argues that the current order intake partly reflects catch-up demand and that the valuation, measured against expected 2028 earnings, has become stretched after a strong run in the share price this year.
The bull case is equally well articulated. Deutsche Bank Research reiterated its buy recommendation and lifted its price target to €101, with analyst Christophe Menard pointing to revenue and order intake beating expectations and confirming the recovery in optronics. BofA, Jefferies and DZ Bank also remain constructive, with targets ranging from €90 to €94. The resulting spread — from €62 to €101 — illustrates just how far apart the market's views on Hensoldt's growth story and valuation risk have drifted.
The Next Catalyst Arrives This Month
Attention now turns to a specific event that could shift the debate: the tender process for the luWES system, an unmanned electronic warfare capability. Management has indicated the procedure will launch in August, with the contract volume estimated at over €1 billion should Hensoldt assume broad system responsibility.
CEO Oliver Dörre has framed the challenge in terms that go beyond any single contract. The bottleneck, he argues, is not defence budgets but industrial capacity and technological innovation. Market observers have latched onto this "industrial execution" theme as the key risk for the second half — the question being how quickly the record backlog can be converted into revenue and, ultimately, cash.
Hensoldt at a turning point? This analysis reveals what investors need to know now.
A Stock Caught Between Momentum and Valuation
Technically, the picture remains constructive for now. The shares trade above their 50-day moving average, which sits at roughly €76.80, suggesting the recent recovery attempt has room to run. Year-to-date the stock is up around 16 percent, though it remains in negative territory on a twelve-month view — evidence of how much ground was lost during the weaker phase.
The company has confirmed its full-year 2026 guidance: revenue is expected to rise to €2.75 billion, with the EBITDA margin in the 18.5 to 19.0 percent band and the book-to-bill ratio maintained at 1.5 to 2.0 — a range the first half already exceeded with its 2.4x reading.
For investors, the equation is unusually finely balanced. A backlog above €10 billion provides a formidable foundation for the coming years, but a negative cash flow and a margin gap that must be closed in the fourth quarter give the sceptics legitimate grounds for caution. With the luWES tender set to begin within weeks and the margin question looming over the year-end, the next few months should go some way toward determining which side of the €62-to-€101 divide turns out to be right.
Ad
Hensoldt Stock: New Analysis - 3 August
Fresh Hensoldt information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
